ATE287270T1 - Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels - Google Patents

Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels

Info

Publication number
ATE287270T1
ATE287270T1 AT95942931T AT95942931T ATE287270T1 AT E287270 T1 ATE287270 T1 AT E287270T1 AT 95942931 T AT95942931 T AT 95942931T AT 95942931 T AT95942931 T AT 95942931T AT E287270 T1 ATE287270 T1 AT E287270T1
Authority
AT
Austria
Prior art keywords
producing
immune deficiency
medicinal product
secondary immune
treating secondary
Prior art date
Application number
AT95942931T
Other languages
English (en)
Inventor
John W Hadden
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of ATE287270T1 publication Critical patent/ATE287270T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT95942931T 1994-11-17 1995-11-16 Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels ATE287270T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34164594A 1994-11-17 1994-11-17
PCT/US1995/015492 WO1996015808A1 (en) 1994-11-17 1995-11-16 Method for making a medicament for treating secondary immunodeficiency

Publications (1)

Publication Number Publication Date
ATE287270T1 true ATE287270T1 (de) 2005-02-15

Family

ID=23338440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942931T ATE287270T1 (de) 1994-11-17 1995-11-16 Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels

Country Status (11)

Country Link
US (1) US5698194A (de)
EP (1) EP0789588B1 (de)
JP (4) JP4440342B2 (de)
AT (1) ATE287270T1 (de)
AU (1) AU694304B2 (de)
CA (1) CA2205430C (de)
DE (1) DE69533941T2 (de)
DK (1) DK0789588T3 (de)
ES (1) ES2236719T3 (de)
PT (1) PT789588E (de)
WO (1) WO1996015808A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3497607B2 (ja) * 1995-05-26 2004-02-16 オリンパス株式会社 接眼光学系及びそれを用いた画像表示装置
DE69739951D1 (de) * 1996-03-04 2010-09-16 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
EP1273304B2 (de) * 1997-02-21 2009-07-15 Amgen Inc. Verwendung von Interleukin-15
US6482389B1 (en) * 1997-10-17 2002-11-19 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
CA2385614A1 (en) * 1999-10-13 2001-04-19 Timothy Johann Multiplex cytokine analysis
CN1527721A (zh) * 2000-09-12 2004-09-08 基因特罗生物治疗公司 含治疗性蛋白混合物的组合物及其生产方法
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
MXPA03003638A (es) 2000-10-27 2004-01-26 Immuno Rx Inc Inmunoterapia con vacuna para pacientes inmunosuprimidos.
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
WO2003035004A2 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20050002899A1 (en) * 2003-07-03 2005-01-06 Eyal Talor Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
CA2536041A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
WO2005120550A2 (en) * 2004-06-04 2005-12-22 Cel-Sci Corporation A method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor
CA2574970A1 (en) * 2004-07-30 2006-02-09 Cel-Sci Corporation A method for managing cholesterol with a serum-free and mitogen-free cytokine mixture
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture
ES2653887T3 (es) 2007-11-28 2018-02-09 Irx Therapeutics, Inc. Procedimiento para aumentar el efecto inmunológico
US8470562B2 (en) * 2008-04-14 2013-06-25 Irx Therapeutics, Inc. IRX-2 modified manufacturing process
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
CN107050430B (zh) 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling

Also Published As

Publication number Publication date
EP0789588A4 (de) 2001-11-28
WO1996015808A1 (en) 1996-05-30
PT789588E (pt) 2005-05-31
US5698194A (en) 1997-12-16
JP2005245455A (ja) 2005-09-15
MX9703626A (es) 1998-12-31
JP2009209164A (ja) 2009-09-17
DE69533941D1 (de) 2005-02-24
ES2236719T3 (es) 2005-07-16
DK0789588T3 (da) 2005-05-30
DE69533941T2 (de) 2005-12-29
JP4440342B2 (ja) 2010-03-24
CA2205430A1 (en) 1996-05-30
JPH10510147A (ja) 1998-10-06
AU694304B2 (en) 1998-07-16
JP2007236395A (ja) 2007-09-20
EP0789588B1 (de) 2005-01-19
AU4411196A (en) 1996-06-17
EP0789588A1 (de) 1997-08-20
CA2205430C (en) 2001-09-04

Similar Documents

Publication Publication Date Title
ATE287270T1 (de) Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
AU7769887A (en) Apparatus and methods of culturing motile microorganisms
EP0239697A3 (en) Apparatus for growing tissue cultures in vitro
CA2087525A1 (en) Adoptive immunotherapy with interleukin-7
DE69333433D1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
AU4277689A (en) Process for producing cultured epidermal sheet, product and method of use
KR960009482B1 (en) Method for preserving transplantable sheets of epithelium cultured in vitro
ES500122A0 (es) Procedimiento para preparar un producto con actividad de ti-po fibronectina
SG47515A1 (en) Plant gum material and use thereof in food products
EP0340783A3 (en) Apparatus for culturing animal cells, method of culturing thereof and diagnostics of the culture
EP0205387A3 (en) Human monocytes cultured in suspension in serum-free medium
EP0362408A4 (en) Method of culturing plant organs and culture vessel therefor
Singer et al. Expression of antigens by cultured epithelial cells: comparison of epidermis and thymic epithelium
Mayyasi et al. Cultivation of L strain (Earle) mouse cells in bacteriological media combined with horse serum
DE3364657D1 (en) Process and apparatus for culture of microorganisms using oxygen-enriched gas
IL88863A0 (en) Method and system for in vitro culture of bovine embryos
GB2233666B (en) Microbacterium strain 851, culture media for same and production of single cell nutrient solution.
JPS6437282A (en) Method and apparatus for culture of microorganism
PT83368A (en) Process for propagating microorganisms in vivo by using cell lines which lack human class ii histocompatibility antigens
EP0299067A4 (de) Zuchtmedium für pflanzen.
GR3031236T3 (en) Process for the preparation of pilocarpine.
PL239589A1 (en) Agent for use reproduction process of cultivable plants by means of tissue culture in vitro and method of increasing reproduction rate of cultivable plants by means of tissue culture in vitro
PL285546A1 (en) Biological culture medium for cell cultures and method of culturing human keratocytes as well as proteinous concentrate
IT1217825B (it) Procedimento ed impianto per la coltura di microorganismi
IL84065A0 (en) Methods and medium for controlled regeneration of cucumis sp.plants in vitro from protoplasts

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0789588

Country of ref document: EP